Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia: the COVID STEROID 2 trial - COVID STEROID 2

Department of Intensive Care, Rigshospitalet0 个研究点目标入组 1,000 人开始时间: 2020年7月17日最近更新: 2022年3月2日

适应症

试验速览

暂无简介。

•All the following criteria must be fulfilled:
•- Aged 18 years or above AND
•- Confirmed SARS-CoV-2 (COVID-19) requiring hospitalisation AND
•- Use of one of the following:
•Invasive mechanical ventilation OR
•Non-invasive ventilation or continuous use of continuous positive airway pressure (CPAP) for hypoxia OR
•Oxygen supplementation with an oxygen flow of at least 10 L/min independent of delivery system
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 400
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 600

•We will exclude patients who fulfil any of the following criteria:
•- Use of systemic corticosteroids in doses higher than 6 mg dexamethasone equivalents for other indications than COVID-19
•- Use of systemic corticosteroids for COVID-19 for 5 days or more
•- Invasive fungal infection
•- Active tuberculosis
•- Fertile woman (< 60 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG
•- Known hypersensitivity to dexamethasone
•- Previously randomised into the COVID STEROID 2 trial
•- Informed consent not obtainable

发起方

Department of Intensive Care, Rigshospitalet